{"id":15593,"date":"2025-01-30T17:52:27","date_gmt":"2025-01-30T17:52:27","guid":{"rendered":"https:\/\/www.colorectalcancercanada.com\/?p=15593"},"modified":"2025-07-30T14:29:00","modified_gmt":"2025-07-30T14:29:00","slug":"symposium-de-lasco-sur-les-cancers-gastro-intestinaux-mises-a-jour-sur-le-cancer-colorectal","status":"publish","type":"post","link":"https:\/\/www.colorectalcancercanada.com\/fr\/blogue\/symposium-de-lasco-sur-les-cancers-gastro-intestinaux-mises-a-jour-sur-le-cancer-colorectal\/","title":{"rendered":"Symposium de l&rsquo;ASCO sur les cancers gastro-intestinaux &#8211; Mises \u00e0 jour sur le cancer colorectal"},"content":{"rendered":"<p><span data-contrast=\"auto\">Le 2025 symposium de la Soci\u00e9t\u00e9 am\u00e9ricaine d&rsquo;oncologie clinique (ASCO) sur les cancers gastro-intestinaux, qui s&rsquo;est tenu du 23 au 25 janvier \u00e0 San Francisco, a mis en \u00e9vidence plusieurs avanc\u00e9es significatives dans la recherche et le traitement du cancer colorectal.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Essai Checkmate-8HW :<\/span><\/b> <b><span data-contrast=\"auto\">Le nivolumab et l&rsquo;ipilimumab donnent de meilleurs r\u00e9sultats que les traitements standard pour le cancer colorectal m\u00e9tastatique MSI-H\/dMMR<\/span><\/b><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Qu&rsquo;est-ce que l&rsquo;essai CheckMate-8HW ?<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/dailynews.ascopubs.org\/do\/checkmate-8hw-nivolumab-ipilimumab-demonstrates-improved-outcomes-over-standard\" target=\"_blank\" rel=\"noopener\"><span data-contrast=\"none\">Un essai de phase 3<\/span><\/a><span data-contrast=\"auto\"> qui a test\u00e9 l\u2019usage unique de nivolumab par rapport \u00e0 la combinaison de <\/span><b><span data-contrast=\"auto\">nivolumab + ipilimumab<\/span><\/b><span data-contrast=\"auto\"> (une combinaison de deux immunoth\u00e9rapies) dans n&rsquo;importe quelle ligne de traitement pour le cancer colorectal m\u00e9tastatique (CCRm) avec <\/span><b><span data-contrast=\"auto\">IMS-E\/dMMR<\/span><\/b><span data-contrast=\"auto\"> (un sous-type g\u00e9n\u00e9tique sp\u00e9cifique qui r\u00e9pond bien \u00e0 l&rsquo;immunoth\u00e9rapie).<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Principales conclusions :<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<ul>\n<li data-leveltext=\"o\" data-font=\"Courier New\" data-listid=\"6\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:1440,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Courier New&quot;,&quot;469769242&quot;:[9675],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;o&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"2\"><span data-contrast=\"auto\">Apr\u00e8s pr\u00e8s de 4 ans de suivi, le traitement combin\u00e9 (nivolumab + ipilimumab) a vu une r\u00e9duction de 38 % du risque de progression du cancer ou de d\u00e9c\u00e8s par rapport au traitement unique (nivolumab).<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li data-leveltext=\"o\" data-font=\"Courier New\" data-listid=\"6\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:1440,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Courier New&quot;,&quot;469769242&quot;:[9675],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;o&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"2\"><span data-contrast=\"auto\">Ces r\u00e9sultats compl\u00e8tent des donn\u00e9es ant\u00e9rieures qui d\u00e9montrent que la combinaison est meilleure que la chimioth\u00e9rapie pour le traitement de premi\u00e8re ligne du CCRm MSI-E\/dMMR.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><span data-contrast=\"auto\">Effets secondaires :<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<ul>\n<li data-leveltext=\"o\" data-font=\"Courier New\" data-listid=\"7\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:1440,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Courier New&quot;,&quot;469769242&quot;:[9675],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;o&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"2\"><span data-contrast=\"auto\">La combinaison th\u00e9rapeutique a provoqu\u00e9 plus d&rsquo;effets secondaires que le nivolumab administr\u00e9 seul :<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li data-leveltext=\"\uf0a7\" data-font=\"Wingdings\" data-listid=\"7\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:2160,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Wingdings&quot;,&quot;469769242&quot;:[9642],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0a7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"3\"><span data-contrast=\"auto\">22% des patients sous traitement combin\u00e9 ont eu des effets secondaires s\u00e9v\u00e8res (de grades 3\/4).<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li data-leveltext=\"\uf0a7\" data-font=\"Wingdings\" data-listid=\"7\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:2160,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Wingdings&quot;,&quot;469769242&quot;:[9642],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0a7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"2\" data-aria-level=\"3\"><span data-contrast=\"auto\">14 % des patients recevant le nivolumab en monoth\u00e9rapie ont \u00e9prouv\u00e9 des effets secondaires graves.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><span data-contrast=\"auto\">\u00c0 retenir :<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<ul>\n<li data-leveltext=\"o\" data-font=\"Courier New\" data-listid=\"8\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:1440,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Courier New&quot;,&quot;469769242&quot;:[9675],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;o&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"2\"><span data-contrast=\"auto\">La combinaison des deux immunoth\u00e9rapies est une option prometteuse pour le CCRm MSI-E\/dMMR, mais la gestion de la toxicit\u00e9 demeure prioritaire.\u00a0 <\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"auto\">Cancer colorectal Canada soumettra, au mois de f\u00e9vrier, les commentaires des patient.e.s et des proches-aidant.e.s \u00e0 l&rsquo;Agence des m\u00e9dicaments du Canada, dans le cadre de son \u00e9valuation du remboursement des m\u00e9dicaments, afin de favoriser l&rsquo;acc\u00e8s des Canadien.ne.s \u00e0 cette combinaison d&rsquo;immunoth\u00e9rapies.<\/span><\/i><span data-ccp-props=\"{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">#GI25 #CCRm<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le 2025 symposium de la Soci\u00e9t\u00e9 am\u00e9ricaine d&rsquo;oncologie clinique (ASCO) sur les cancers gastro-intestinaux, qui s&rsquo;est tenu du 23 au 25 janvier \u00e0 San Francisco, a mis en \u00e9vidence plusieurs avanc\u00e9es significatives dans la recherche et le traitement du cancer colorectal.\u00a0 \u00a0 Essai Checkmate-8HW : Le nivolumab et l&rsquo;ipilimumab donnent <a href=\"https:\/\/www.colorectalcancercanada.com\/fr\/blogue\/symposium-de-lasco-sur-les-cancers-gastro-intestinaux-mises-a-jour-sur-le-cancer-colorectal\/\">&#8230;<\/a><\/p>\n","protected":false},"author":5,"featured_media":15611,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"0","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[42,98],"tags":[],"class_list":["post-15593","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogue","category-research-updates-fr"],"_links":{"self":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/15593","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/comments?post=15593"}],"version-history":[{"count":0,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/posts\/15593\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media\/15611"}],"wp:attachment":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media?parent=15593"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/categories?post=15593"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/tags?post=15593"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}